Premaitha signs with two South East Asia labs

International molecular diagnostics group Premaitha Health announced on Monday that it signed contracts with two “significant laboratories” in South East Asia through its Taiwanese subsidiary, Yourgene Bioscience.

The AIM-traded firm said the agreements had been signed with two partners for laboratories which are in different countries in South East Asia, and would be established as regional hubs for NIPT.

Both partners were already established providers of NIPT in their domestic markets, the board explained, with ambitions to further expand across the region.

One partner was also amongst the largest listed genomic testing companies in Asia, it claimed, and would market the test under its own brand.

“South East Asia is a very important region for Premaitha as the NIPT market is well-established and growing apace,” said chief executive Dr Stephen Little.

“These newly secured market leading partners will increase Premaitha's presence in the region, whilst further expanding our routes to market.

“We continue to work with our partners globally to increase awareness of the benefits of NIPT as we seek to further strengthen our footprint.”